Ionis Pharmaceuticals (IONS) has further good news with a new revelation from Akcea Therapeutics, a wholly-owned subsidiary of Ionis Pharmaceuticals that the Phase 3 COMPASS study met its primary endpoint.
COMPASS is a randomized, double-blind, placebo-controlled, 26-week Phase 3 study evaluating the firm’s drug volanesorsen in 113 patients with severe hypertriglyceridemia.
The average incoming triglyceride level of patients in the study was 1,261 mg/dl. Patients treated with volanesorsen experienced clinically meaningful benefits on triglycerides as summarized below:
- For the primary endpoint of the study, volanesorsen-treated patients . . .